AIDS-related malignant lymphoma: results of prospective treatment trials.

• DOI: 10.1200/jco.1987.5.9.1322
• Publication Date: 2017-02-23T13:28:49Z
• Authors: P S Gill; A M Levine; M Krailo; M U Rarick; C Loureiro; L Deyton; P Meyer; S Rasheed
• Keywords: Regimen; Group B

Twenty-two consecutive patients with high-grade, B-cell lymphomas related to the acquired immunodeficiency syndrome (AIDS) were accrued onto two sequential phase II studies, consisting of a standard regimen (M-BACOD, group no. 1, N = 13), or novel, intensive (group 2, 9), which included high-dose cytosine arabinoside (HD-Ara-C), and methotrexate (HD-MTX), in an attempt prevent CNS relapse improve response rates. Stage IV disease was present 82%. Complete remission (CR) achieved seven 13 (54%) three nine (33%) 2 (P NS). By multivariate analysis, most significant factor predicting Karnofsky performance score (KPS) greater than 60 .04). Three ten who CR on either have relapsed; all, five (31%) 1 disease-free survival for more year, compared one (11%) 2. progression occurred six 1. Hematologic toxicity significantly these had increased risk opportunistic infection (one v 2; P less .01). Survival similar, median 11 months 6 We conclude that combination chemotherapy described here is associated early death due AIDS-related lymphoma, remains major problem. Trials nature, perhaps immunomodulators antiretroviral agents should be explored.